01 — At a Glance
The Pharma Darling Goes MedTech. The Markets Yawned.
- 52-Week High / Low₹5,934 / ₹4,608
- Q3 FY26 Revenue₹3,737 Cr
- Q3 FY26 PAT₹653 Cr
- Q3 EPS (₹)53.19
- Annualised EPS (Q3×4)₹212.76
- Book Value₹1,116
- Price to Book4.95x
- Dividend Yield0.81%
- Debt / Equity0.18x
- Occlutech Deal₹1,100 Cr (~55%)
Auditor’s Note: Alkem just announced it’s acquiring 51–55% of Switzerland-based Occlutech (cardiac devices) for EUR 99.4 million (~₹1,100 crore). The pharma stock rallied sideways on this news because apparently, the market was already pricing in some diversification premium. P/E at 27.5x is nearly in line with peers. Revenue growth at 10.7% QoQ and 11.7% YTD. Meanwhile, ROCE sits at a respectable 20.4%, and they’re holding ₹4,081 crore in unencumbered cash. Everything screams “capital deployment time.” And they finally listened.
02 — Introduction
The Pharma Company That Suddenly Remembered: “Healthcare Is Bigger Than Pills”
Alkem Laboratories. Fifth-largest pharma company in India by market share (4.1%). A 1973-founded heavyweight in the business of making human beings slightly less sick through the miracle of tablets, capsules, and injectable solutions. Ranking #1 in anti-infectives. Top 3 in GI meds, pain killers, and vitamins. You know their brands even if you don’t know Alkem: CLAVAM, PAN, SUMO, Taxim-O. Your neighbourhood medical shop has a stack of them.
The stock has been a quiet compounding machine. Over the past three years, it’s delivered a 20% annualised return. Five years? 15%. Not flashy, not a 10x story, but steady cash-generating growth with a dividend payout of 37% and a management that doesn’t do stunts.
Then, on February 13, 2026, they announced something genuinely interesting: A binding offer to acquire up to 55% of Occlutech Holding AG — a Germany-headquartered, Switzerland-domiciled medical device company specialising in minimally invasive cardiac structural heart devices. Market cap of Occlutech: EUR 180.70 million. Alkem’s proposed cheque: EUR 99.4 million for 51–55% control. Expected close by June 2026.
The move signals Alkem is finally deploying its fortress balance sheet into something beyond incrementally optimising formulation margins. For a company sitting on ₹4,081 crore in liquid cash and generating ₹1,500+ crore in annual operating cash flow, the move makes mathematical sense. The question is: Does it make strategic sense? Let’s unpack the numbers, the logic, and whether the Indian investor market is ready for Alkem 2.0.
From the Feb 18, 2026 Investor Meet: Alkem MedTech CEO Kaustav Banerjee (30+ years in global medical devices, ex-VP South Asia at Zimmer, ex-MD at St. Jude Medical) walked through the vision: “Going deep and going wide” — structural heart as the anchor, ortho implants already scaling, and rest-of-world (ROW) expansion as the play. If this is your first MedTech rodeo, it’s either genius or expensive hubris. History will tell.
03 — Business Model: Pills + Implants = What Could Go Wrong?
They Make Drugs. Now They Want To Make Devices. Separately.
Alkem’s core business: Design, manufacture, and distribute pharmaceutical formulations across India (70% of revenue) and 40+ countries globally (30%). Scale of 12,500+ field force. Distribution to 8,400+ stockists. 18 manufacturing facilities across India and the US, with 6 USFDA-approved sites. Revenue in FY25: ₹12,965 crore. Profit: ₹2,215 crore. Margins stable at 19–20% operating, 17% PAT. The machine has been humming for decades.
But pharma margins are under perpetual pressure. India has price controls (30% of Alkem’s portfolio is under DPCO). Global generics are a race to the bottom. Chronic therapies are growing but still a small part of the mix. So management asked a reasonable question: “Why are we hoarding cash?” And thus, Alkem MedTech was born.
Alkem MedTech strategy: Two pillars. First, orthopedic implants (knee, hip, trauma) — organic play with manufacturing in India, CE approvals by Q4 FY28, India market entry by Q2 FY27, targeting 10% market share in large joints by year 5. Second, cardiovascular/structural heart — via the Occlutech acquisition. LAA closure devices (left atrial appendage, currently in FDA review), ASD/VSD closure, PDA occluders, AFR devices for heart failure. Occlutech is #3 globally, #2 in Europe, in a $1.4 billion LAA market alone.
Domestic Market70%of pharma revenue
Global Pharma30%of pharma revenue
MedTech Path5Yto profitability
Occlutech 2025€50 Mnrevenue run rate
Two Parallel Universes: Alkem’s existing pharma business runs on 70% India domestic, high volume, price-controlled, tight margins. Alkem MedTech will run on established market approvals, premium pricing, global distribution, and much lower volume but 60–70% gross margins. The businesses are structurally opposite. Management’s bet: Both can co-exist, neither cannibalises the other, and MedTech becomes 20% of group EBITDA by FY30.
💬 Would you buy a pharma stock that’s now also a medical device company? Or does vertical expansion scare you?
04 — Financials Overview
Q3 FY26: The Numbers
Result type: Quarterly Results | Q3 FY26 EPS: ₹53.19 | Annualised EPS (Q3×4): ₹212.76 | Full-year FY25 EPS: ₹181.11
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 3,737 | 3,374 | 4,001 | +10.7% | -6.6% |
| Operating Profit | 828 | 759 | 921 | +9.1% | -10.1% |
| OPM % | 22% | 23% | 23% | -100 bps | -100 bps |
| PAT | 653 | 641 | 779 | +1.9% | -16.2% |
| EPS (₹) | 53.19 | 52.34 | 63.99 | +1.6% | -16.9% |
The Seasoning: Q3 is always softer than Q2 in pharma (seasonality + summer inventory adjustments). Revenue fell 6.6% QoQ and 10.7% YoY growth, but that’s actually respectable for the October-December quarter. OPM at 22% is down 100 bps YoY due to one-time expenses (likely related to MedTech integration and Occlutech due diligence). PAT nearly flat YoY despite revenue growth — that’s the tax rate + other income dynamic at play. The real story is in YTD: 9M FY26 revenues are ₹11,108 crore (vs. ₹9,821 crore in 9M FY25), a clean 13% growth. Management guided to FY26 revenue growth of 12–13%. You’re on track. Sleep well.
05 — Valuation: Fair Value Range
What’s This Company Actually Worth? (Pharma + MedTech Beta)
Join 10,000+ investors who read this every week.
